The one thing that cardiologists and cardiovascular device companies can agree on when it comes to vulnerable plaque (VP) is that it's too soon to know what they can agree on. But Guidant Corp. , perhaps chastened by its lagging efforts in drug-eluting stents, is not taking any chances on missing out on what some experts believe could be the next major cardiovascular device opportunity. The company appears to be the leader among the large cardiology device competitors in targeting vulnerable plaque, having begun its efforts in 1999.
Guidant's latest move in this space is a collaboration with Miravant Medical Technologies Inc. in an effort to investigate...